Navigation Links
Inflammatory mediator enhances plaque formation in Alzheimer’s disease
Date:9/7/2011

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that causes progressive cognitive impairment and memory loss. Now, a new study published by Cell Press in the September 8 issue of the journal Neuron identifies a previously unrecognized link between neuroinflammation and the classical pathological brain changes that are the hallmark of the disease. In addition, the research identifies a new potential therapeutic target for AD.

AD is characterized by abnormal accumulation of amyloid Β (AΒ) protein plaques and neurofibrillary tangles of tau protein in the brain. In addition to these classical hallmarks, neuroinflammation has also been identified as a major component of the disease. Previous research has suggested that AD associated inflammation increases the inducible nitric oxide synthase (NOS2) in neurons and support cells. Importantly, NOS2 leads to generation of nitric oxide (NO) which has been linked with neurodegeneration.

"One of the fingerprints of NO is tyrosine nitration, a posttranslational protein modification that can induce structural changes leading to protein aggregation," explains senior study author, Dr. Michael T. Heneka, from the University of Bonn in Germany. "Since there is so far no mechanistic explanation how expression of NOS2 and the subsequent production of NO and its reaction products modulate AΒ and thereby the progression of AD, we speculated that nitration of AΒ might contribute to AD pathology."

In their study, first author Dr. Markus P. Kummer and colleagues discovered that AΒ is a novel NO target. They observed nitrated AΒ in AD and AD mouse models and found that this modification accelerated the deposition of human AΒ. Importantly, reduction of NOS2 reduced AΒ deposition and memory deficits in a mouse model of AD. Further, nitrated AΒ induced the formation of amyloid plaques when injected into the brains of mice with genetic mutations associated with AD.

"Taken together, our results identify a novel modification of AΒ, tyrosine nitration, and propose a causative link between the AΒ cascade, activation of NOS2, and the subsequent increase in its reaction product nitric oxide during AD," concludes Dr. Heneka. "We think that nitrated AΒ may serve as marker of early AΒ plaque formation. More importantly, it may be a promising target for an AD therapy, and that application of specific inhibitors of NOS2 may therefore open a new therapeutic avenue in AD."


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. NIH grant will create behavioral health registry for pediatric inflammatory bowel disease
3. Prozac and Celexa exhibit anti-inflammatory effects
4. Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula
5. Feedback loop explains inflammatory effect on intestinal lining
6. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
7. Two New Phytochemicals with Anti-Inflammatory Activity Found in Noni Fruit
8. New research reinforces anti-inflammatory properties of tart cherries
9. First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease
10. POP ROCK BAND Honor Society Drummer Advocates for Inflammatory Bowel Disease Patients on Capitol Hill in Conjunction with World IBD Day
11. Crohn's & Colitis Foundation National Event Helping Women Manage Inflammatory Bowel Disease: Two Women Physician Experts and Researchers in IBD on Interactive Webcast/Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: